| |
|
(Simultaneous Translation)
|
|
Tuesday
May 9, 2006
|
|
Program Overview |
| |
Cancer
remains one of the most vexing health care problems facing the world,
both in terms of therapy and cost. This is not for want of effort by
institutions and businesses seeking solutions. There has been a
proliferation of entities addressing the problem and a multitude of
proposed solutions. Both Japan and the United States have been leaders
in discovery and adoption of new therapeutic approaches. Progress had
been slow, but there has been progress in fighting many forms of
cancer. The amount of money being spent in cancer therapeutics research
continues to grow. The 7th Annual Philadelphia-Japan Health Sciences
Dialogue, featuring distinguished leaders in the field, is designed to
take stock of what is happening in Japan and the United States in the
fight against cancer, and to discern future trends in this important
effort. |
| |
|
|
| 8:15 - 8:25 AM |
|
Welcome |
| |
|
Hiroshi Sato
Deputy Consul General and Deputy Chief of Mission, Consulate General of Japan in New York |
| |
|
|
| 8:30 - 8:50 AM |
|
Opening Remarks: Transformational Changes in Cancer Research and Treatment |
| |
|
Robert C. Young, M.D.
President, Fox Chase Cancer Center |
| |
|
|
| 8:50 - 10:00 AM |
|
Distinction and Similarities: Three Perspectives |
| |
|
Richard G. Pestell, M.D., Ph.D.
Director, Kimmel Cancer Center, Thomas Jefferson University Hospital
Yasuhiro Fujiwara, M.D.
Director, Outpatient Treatment Center, Japan National Cancer Center
Frank Pasqualone
Senior Vice President, Oncology, Bristol-Myers Squibb Co.
|
| |
|
|
| 10:15 - 11:30 AM |
|
Evolving Trends in Cancer Therapy |
| |
|
Jeffery M. Bockman, Ph.D.
Vice President, Defined Health
David Jenkins
Director, Clinical Development, Cervarix TM, GlaxoSmithKline Biologicals
William U. Shipley, M.D.
Massachusetts General Hospital Cancer Center |
| |
|
|
| 11:30 - 12:15 PM |
|
The Product Pipeline: Targeted ≠ Narrow |
| |
|
Karen Bernstein
Chairman & Editor-in-Chief, BioCentury |
| |
|
|
| 12:15 - 1:45 PM |
|
Luncheon Address: Diagnostics & Biomarkers |
| |
|
Sean McDonald
President and CEO, Precision Therapeutics, Inc.
Moderator: Pradip K. Banerjee, Ph.D.
President and CEO, The Science Center |
| |
|
|
| 1:45 - 2:30 PM |
|
The Unique Quality of Cancer Clinical Trials |
| |
|
Philip Sass, Ph.D.
Executive Vice President & Chief Operating Officer, Morphotek Inc.
Linda Faux
Senior Director, Clinical Project Management, AstraZeneca Pharmaceuticals |
| |
|
|
| 2:30 - 3:30 PM |
|
Licenses and Business Development: Big Pharma |
| |
|
Ben Bonifant
Senior Practice Executive, Business Development Practice, Campbell Alliance
Nobuo Hanai, Ph.D.
President and CEO, BioWa, Inc. |
| |
|
|
| 3:45 - 4:45 PM |
|
Licenses and Business Development: The Biotechs |
| |
|
John Gill
President & CEO, Gentara Corporation
Ronald A. Pepin, Ph.D.
Senior Vice President, Business Development, Medarex, Inc.
Masashi Suganuma, M.D.
Ph.D., Vice President & COO, CanBas Co., Ltd. |
| |
|
|
| 4:45 - 5:00 PM |
|
Closing Remarks |
| |
|
Richard G. Pestell, M.D., Ph.D.
Director, Kimmel Cancer Center, Thomas Jefferson University Hospital |
| |
|
|
| 5:00 - 6:30 PM |
|
Cocktail Networking Reception |
